Research Perspectives:

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

Jan Philipp Bewersdorf and Amer M. Zeidan _

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2021; 12:1314-1317. https://doi.org/10.18632/oncotarget.27919

Metrics: PDF 690 views  |   Full Text 918 views  |   ?  


Jan Philipp Bewersdorf1 and Amer M. Zeidan1,2

1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA

2 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA

Correspondence to:

Amer M. Zeidan,email: amer.zeidan@yale.edu

Keywords: acute myeloid leukemia; AML; PLK-1 inhibitor; onvansertib; volasertib

Received: February 24, 2021     Accepted: March 08, 2021     Published: June 22, 2021

Copyright: © 2021 Bewersdorf and Zeidan. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27919